



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Stomatology

ESPS Manuscript NO: 4446

Title: Molecular biomarkers of cell proliferation in ameloblastomas. A mini-review

Reviewer code: 00573538

Science editor: Song, Xiu-Xia

Date sent for review: 2013-06-30 13:06

Date reviewed: 2013-07-14 19:54

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Journal: World Journal of Stomatology Manuscript Number: ESPS Manuscript NO: 4446 Title: Molecular biomarkers of cell proliferation in ameloblastomas. A mini-review Article Type: Review article Referee Report Comments for authors Major comments: In this review, the authors discuss the use of several classical molecular proliferation markers, including Ki-67, PCNA, cyclin D1, and DNA topoisomerase II alpha, for characterizing ameloblastomas. They also propose the potential use of three new proliferation markers (geminin, MCM, mitosin), which have been used to characterize other neoplasms. They suppose that the use of these biomarkers helps evaluate the biological behavior of this type of odontogenic tumor. Although this review paper was well written and is of great interest, this reviewer has reservations as follows: 1) The authors discussed and summarized several molecular biomarkers of cell proliferation in ameloblastomas; however, they did not discuss the potential applications of these biomarkers for this disease in the clinic. For example: (i) What is the possibility and reliability of using these biomarkers for diagnosis of ameloblastomas in the clinic, as compared to other clinical parameters of odontogenic tumor disease activity? (ii) Whether these biomarkers can be used for monitoring response to therapy or treatment effectiveness in ameloblastomas? (iii) Whether these biomarkers can be used for monitoring disease progression and prognosis in patients with ameloblastomas? 2) Besides AgNOR and IHC mentioned in the manuscript, are there any other methods and techniques like the mitotic index, flow cytometry, western blotting, or real-time qPCR that can be used for detecting the expression or levels of these biomarkers in ameloblastoma patients? If so, which method or technique is better than others in terms of sensitivity and specificity as well as feasibility? For example, which method or technique is simpler and easier than other techniques for the diagnosis of ameloblastomas, making it a more



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

practical method for use in primary care clinics and hospitals in developing countries, which may lack sophisticated equipment and facilities. The authors may want to discuss about these issues in this paper. Minor comments: 1) All of the authors' affiliations in the paper should be in English. 2) Pay more attention to the punctuation mark throughout the manuscript. 3) The conclusion section needs to be revised. For instance, the authors should give perspective remarks on the future research of biomarkers in ameloblastomas, and whether and how these marker proteins can be potentially used as biomarkers for diagnosis and prognosis of ameloblastomas and for monitoring therapy response and disease progression in patients with ameloblastomas. 4) The authors should give a brief figure legend to Figure 1 and some brief information in the footnote of Table 1 to help the reader fully understand Figure 1 and Table 1 without referring to the text of the paper. 5) Some sentences in the manuscript are confusion. e.g. "MCM proteins are expressed cells in all phases of the cell cycle," on page 7. The authors need to carefully edit this submission before the paper could be published in an English-language journal.